- Report
- September 2022
- 142 Pages
Asia Pacific
From €1996EUR$2,100USD£1,712GBP
€2852EUR$3,000USD£2,446GBP
- Report
- June 2022
- 150 Pages
Global
From €3028EUR$3,185USD£2,597GBP
€4325EUR$4,550USD£3,710GBP
- Report
- July 2020
- 130 Pages
Global
From €3422EUR$3,600USD£2,936GBP
- Report
- November 2020
- 318 Pages
Global
From €3803EUR$4,000USD£3,262GBP
- Report
- May 2022
- 89 Pages
Global
From €3500EUR$3,944USD£3,107GBP
- Report
- October 2023
- 146 Pages
Global
From €3353EUR$3,528USD£2,876GBP
€3945EUR$4,150USD£3,384GBP
- Report
- October 2022
- 271 Pages
Global
From €3394EUR$3,570USD£2,911GBP
- Report
- February 2024
- 180 Pages
Global
From €5228EUR$5,499USD£4,484GBP
- Book
- October 2018
- 456 Pages
- Book
- May 2014
- 616 Pages
- Book
- May 2023
North America
- Book
- April 2018
North America
The Lung Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of tests and technologies that can detect and diagnose lung cancer. These tests can range from imaging techniques such as X-ray, CT scan, and MRI, to molecular tests such as gene sequencing and biomarker analysis. The goal of these tests is to detect lung cancer at an early stage, when it is most treatable.
The Lung Cancer Diagnostics market is highly competitive, with many companies offering a variety of tests and technologies. Some of the major players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Hologic, and Becton Dickinson. Show Less Read more